Skip to content
Catalyst

melatoninFinding

Melatonin has no detected effect on malondialdehyde (circulating)

no difference foundModerate evidenceFinding

01 · The sentence it was drawn from

“Also, the MLT group demonstrated marginal reduction in MDA compared to placebo group (F = 3.046, p = 0.092, partial η2 = 0.095), revealing a trend towards decreased oxidative stress that did not reach statistical significance.”
Quoted verbatim from Evaluating the antioxidant and anti-inflammatory effect of melatonin in pediatric hemodialysis patients: a randomized, placebo-controlled trial.
This finding among the 39 findings on its endpoint

melatonin

Malondialdehyde (circulating)

no difference found

Who
children on chronic haemodialysis; primary endpoint, ANCOVA adjusted for baseline MDA and antihypertensive use; serum MDA by ELISA
Dose studied
5 mg oral melatonin once daily 1 h before bedtime for 12 weeks

Moderate evidencePMID 41565787 · 2026

02 · The study

Study
RCT
Duration
3 months

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

03 · The paper

Scientific reports

Evaluating the antioxidant and anti-inflammatory effect of melatonin in pediatric hemodialysis patients: a randomized, placebo-controlled trial.

2026PMID 41565787doi 10.1038/s41598-025-34264-0

A later check left this paper out of the papers counted for melatonin; the finding stays because it matches the quoted sentence.

What else it reported1 finding · 1 compound · 1 endpoint

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M3R2JMQ36NNA29QDT7N5TJ4B